BACKGROUND: While the published short-term oncologic outcomes after laparoscopic radical prostatectomy (LRP) are encouraging, intermediate and long-term data are lacking. OBJECTIVE: We analyzed the oncologic outcome after LRP based on 10 yr of experience. DESIGN, SETTING, AND PARTICIPANTS: This retrospective analysis of data prospectively collected from 1998 to 2007 studies 1564 consecutive patients with clinically localized prostate cancer (cT1c-cT3a) who underwent LRP. INTERVENTION: LRP was performed by two surgeons at either L'Institut Mutualiste Montsouris (IMM) in Paris, France, or Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City, USA. MEASUREMENTS: Progression of disease was defined as a prostate-specific antigen (PSA) of >or=0.1 ng/ml with confirmatory rise or initiation of secondary therapy. Patients were stratified as low, intermediate, or high risk based on the pretreatment prostate cancer nomogram progression-free probability of >90%, 89-71%, and <70%, respectively. RESULTS AND LIMITATIONS: The overall 5-yr and 8-yr probability of freedom from progression (PFP) was 78% (95% confidence interval [CI], 74-82%) and 71% (95% CI, 63-78%), respectively. For low-, intermediate-, and high-risk cancer, the 5-yr PFP was 91% (95% CI, 85-95%), 77% (95% CI, 71-82%), and 53% (95% CI, 40-65%), respectively. Surgical margins (SMs) were positive in 13% of the cases. Nodal metastases were detected in 3% of the patients after limited pelvic lymph node dissection (PLND) and in 10% after a standard PLND (p<0.001). The 3-yr PFP for node-positive patients was 49%. There were 22 overall deaths and 2 deaths from prostate cancer. CONCLUSIONS: LRP provided 5- and 8-yr cancer control in 78% and 71% of patients, respectively, with clinically localized prostate cancer and in 53% of those with high-risk cancer at 5 yr. A PLND limited to the external iliac nodal group is inadequate for detecting nodal metastases.
BACKGROUND: While the published short-term oncologic outcomes after laparoscopic radical prostatectomy (LRP) are encouraging, intermediate and long-term data are lacking. OBJECTIVE: We analyzed the oncologic outcome after LRP based on 10 yr of experience. DESIGN, SETTING, AND PARTICIPANTS: This retrospective analysis of data prospectively collected from 1998 to 2007 studies 1564 consecutive patients with clinically localized prostate cancer (cT1c-cT3a) who underwent LRP. INTERVENTION: LRP was performed by two surgeons at either L'Institut Mutualiste Montsouris (IMM) in Paris, France, or Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City, USA. MEASUREMENTS: Progression of disease was defined as a prostate-specific antigen (PSA) of >or=0.1 ng/ml with confirmatory rise or initiation of secondary therapy. Patients were stratified as low, intermediate, or high risk based on the pretreatment prostate cancer nomogram progression-free probability of >90%, 89-71%, and <70%, respectively. RESULTS AND LIMITATIONS: The overall 5-yr and 8-yr probability of freedom from progression (PFP) was 78% (95% confidence interval [CI], 74-82%) and 71% (95% CI, 63-78%), respectively. For low-, intermediate-, and high-risk cancer, the 5-yr PFP was 91% (95% CI, 85-95%), 77% (95% CI, 71-82%), and 53% (95% CI, 40-65%), respectively. Surgical margins (SMs) were positive in 13% of the cases. Nodal metastases were detected in 3% of the patients after limited pelvic lymph node dissection (PLND) and in 10% after a standard PLND (p<0.001). The 3-yr PFP for node-positive patients was 49%. There were 22 overall deaths and 2 deaths from prostate cancer. CONCLUSIONS: LRP provided 5- and 8-yr cancer control in 78% and 71% of patients, respectively, with clinically localized prostate cancer and in 53% of those with high-risk cancer at 5 yr. A PLND limited to the external iliac nodal group is inadequate for detecting nodal metastases.
Authors: B Guillonneau; H el-Fettouh; H Baumert; X Cathelineau; J D Doublet; G Fromont; G Vallancien Journal: J Urol Date: 2003-04 Impact factor: 7.450
Authors: Gerald W Hull; Farhang Rabbani; Farhat Abbas; Thomas M Wheeler; Michael W Kattan; Peter T Scardino Journal: J Urol Date: 2002-02 Impact factor: 7.450
Authors: Christian P Pavlovich; Bruce J Trock; Aaron Sulman; Andrew A Wagner; Lynda Z Mettee; Li-Ming Su Journal: J Urol Date: 2008-01-22 Impact factor: 7.450
Authors: Karim Touijer; James A Eastham; Fernando P Secin; Javier Romero Otero; Angel Serio; Jason Stasi; Rafael Sanchez-Salas; Andrew Vickers; Victor E Reuter; Peter T Scardino; Bertrand Guillonneau Journal: J Urol Date: 2008-03-18 Impact factor: 7.450
Authors: Jonas Busch; Carsten Stephan; Annett Klutzny; Stefan Hinz; Carsten Kempkensteffen; Ergin Kilic; Michael Lein; Steffen Weikert; Kurt Miller; Ahmed Magheli Journal: World J Urol Date: 2012-05-11 Impact factor: 4.226